126 related articles for article (PubMed ID: 31145011)
1. Serum MiRNA-27a as potential diagnostic nucleic marker for breast cancer.
Swellam M; Zahran RFK; Ghonem SA; Abdel-Malak C
Arch Physiol Biochem; 2021 Feb; 127(1):90-96. PubMed ID: 31145011
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of color Doppler ultrasound combined with plasma miR-21 and miR-27a in the diagnosis of breast cancer.
Li M; Li Q; Yin Q; Wang Y; Shang JM; Wang LH
Clin Transl Oncol; 2021 Apr; 23(4):709-717. PubMed ID: 33206330
[TBL] [Abstract][Full Text] [Related]
3. Clinical significance of blood-based miRNAs as diagnostic and prognostic nucleic acid markers in breast cancer: Comparative to conventional tumor markers.
Swellam M; Ramadan A; El-Hussieny EA; Bakr NM; Hassan NM; Sobeih ME; EzzElArab LR
J Cell Biochem; 2019 Aug; 120(8):12321-12330. PubMed ID: 30825229
[TBL] [Abstract][Full Text] [Related]
4. Potential diagnostic role of circulating MiRNAs in breast cancer: Implications on clinicopathological characters.
Swellam M; El Magdoub HM; Hassan NM; Hefny MM; Sobeih ME
Clin Biochem; 2018 Jun; 56():47-54. PubMed ID: 29679553
[TBL] [Abstract][Full Text] [Related]
5. In vivo and in vitro effects of microRNA-27a on proliferation, migration and invasion of breast cancer cells through targeting of SFRP1 gene via Wnt/β-catenin signaling pathway.
Kong LY; Xue M; Zhang QC; Su CF
Oncotarget; 2017 Feb; 8(9):15507-15519. PubMed ID: 28099945
[TBL] [Abstract][Full Text] [Related]
6. Clinical aspects of circulating miRNA-335 in breast cancer patients: A prospective study.
Swellam M; Mahmoud MS; Hashim M; Hassan NM; Sobeih ME; Nageeb AM
J Cell Biochem; 2019 Jun; 120(6):8975-8982. PubMed ID: 30506730
[TBL] [Abstract][Full Text] [Related]
7. Serum microRNA-195 is down-regulated in breast cancer: a potential marker for the diagnosis of breast cancer.
Zhao FL; Dou YC; Wang XF; Han DC; Lv ZG; Ge SL; Zhang YK
Mol Biol Rep; 2014 Sep; 41(9):5913-22. PubMed ID: 25103018
[TBL] [Abstract][Full Text] [Related]
8. Down-regulation of microRNA-26a and up-regulation of microRNA-27a contributes to aggressive progression of human osteosarcoma.
Taheriazam A; Bahador R; Karbasy SH; Jamshidi SM; Torkaman A; Yahaghi E; Shakeri M
Diagn Pathol; 2015 Sep; 10():166. PubMed ID: 26377680
[TBL] [Abstract][Full Text] [Related]
9. EXPRESSION PROFILE OF miR-145, -182, -21, -27a, -29b, and -34a IN BREAST CANCER PATIENTS OF YOUNG AGE.
Chekhun V; Borikun T; Mushii O; Zadvornyi T; Martyniuk О; Kashuba E; Bazas V; Hrybach S; Krotevych M; Lyalkin S; Lukianova N
Exp Oncol; 2024 Feb; 45(4):421-431. PubMed ID: 38328848
[TBL] [Abstract][Full Text] [Related]
10. Decreased serum miR-181a is a potential new tool for breast cancer screening.
Guo LJ; Zhang QY
Int J Mol Med; 2012 Sep; 30(3):680-6. PubMed ID: 22692639
[TBL] [Abstract][Full Text] [Related]
11. Role of some circulating MiRNAs on breast cancer diagnosis.
Swellam M; Zahran RFK; Abo El-Sadat Taha H; El-Khazragy N; Abdel-Malak C
Arch Physiol Biochem; 2019 Dec; 125(5):456-464. PubMed ID: 29925280
[TBL] [Abstract][Full Text] [Related]
12. MiR-27 as a prognostic marker for breast cancer progression and patient survival.
Tang W; Zhu J; Su S; Wu W; Liu Q; Su F; Yu F
PLoS One; 2012; 7(12):e51702. PubMed ID: 23240057
[TBL] [Abstract][Full Text] [Related]
13. Serum miRNA-27a and miRNA-18b as potential predictive biomarkers of hepatitis C virus-associated hepatocellular carcinoma.
Rashad NM; El-Shal AS; Shalaby SM; Mohamed SY
Mol Cell Biochem; 2018 Oct; 447(1-2):125-136. PubMed ID: 29455432
[TBL] [Abstract][Full Text] [Related]
14. Identification of serum exosomal miR-148a as a novel prognostic biomarker for breast cancer.
Li D; Wang J; Ma LJ; Yang HB; Jing JF; Jia MM; Zhang XJ; Guo F; Gao JN
Eur Rev Med Pharmacol Sci; 2020 Jul; 24(13):7303-7309. PubMed ID: 32706068
[TBL] [Abstract][Full Text] [Related]
15. Circulating miR-99a-5p Expression in Plasma: A Potential Biomarker for Early Diagnosis of Breast Cancer.
Garrido-Cano I; Constâncio V; Adam-Artigues A; Lameirinhas A; Simón S; Ortega B; Martínez MT; Hernando C; Bermejo B; Lluch A; Lopes P; Henrique R; Jerónimo C; Cejalvo JM; Eroles P
Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33050096
[TBL] [Abstract][Full Text] [Related]
16. Study on the relationship between miR-520g and the development of breast cancer.
Ren GB; Wang L; Zhang FH; Meng XR; Mao ZP
Eur Rev Med Pharmacol Sci; 2016; 20(4):657-63. PubMed ID: 26957267
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic values of microRNA 27a in breast cancer patients.
Seddik MI; Osama O; Jabir MA; Abdelrahman EM; Nigm DA
Egypt J Immunol; 2021 Jul; 28(3):127-137. PubMed ID: 34185461
[TBL] [Abstract][Full Text] [Related]
18. Identification of serum miR-1915-3p and miR-455-3p as biomarkers for breast cancer.
Guo J; Liu C; Wang W; Liu Y; He H; Chen C; Xiang R; Luo Y
PLoS One; 2018; 13(7):e0200716. PubMed ID: 30048472
[TBL] [Abstract][Full Text] [Related]
19. Dysregulation of miR-122, miR-574 and miR-375 in Egyptian patients with breast cancer.
Elghoroury EA; Abdelghafar EE; Kamel S; Awadallah E; Shalaby A; El-Saeed GSM; Mahmoud E; Kamel MM; Abobakr A; Yousef RN
PLoS One; 2024; 19(5):e0298536. PubMed ID: 38820252
[TBL] [Abstract][Full Text] [Related]
20. Combined detection of plasma miR-127-3p and HE4 improves the diagnostic efficacy of breast cancer.
Lu M; Ju S; Shen X; Wang X; Jing R; Yang C; Chu H; Cong H
Cancer Biomark; 2017; 18(2):143-148. PubMed ID: 27983524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
